Atea Pharmaceuticals Inc AVIR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/19/22 EDT
7.25UNCH (UNCH)
Volume
46,999
Close
7.25quote price arrow up+0.11 (+1.54%)
Volume
888,309
52 week range
5.31 - 46.91
Loading...
  • Open7.14
  • Day High7.62
  • Day Low7.11
  • Prev Close7.25
  • 52 Week High46.91
  • 52 Week High Date10/04/21
  • 52 Week Low5.31
  • 52 Week Low Date05/09/22

Key Stats

  • Market Cap603.64M
  • Shares Out83.26M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-18.9

KEY STATS

  • Open7.14
  • Day High7.62
  • Day Low7.11
  • Prev Close7.25
  • 52 Week High46.91
  • 52 Week High Date10/04/21
  • 52 Week Low5.31
  • 52 Week Low Date05/09/22
  • Market Cap603.64M
  • Shares Out83.26M
  • 10 Day Average Volume0.91M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-18.9

RATIOS/PROFITABILITY

  • EPS (TTM)0.51
  • P/E (TTM)14.27
  • Fwd P/E (NTM)-3.20
  • EBITDA (TTM)154.301M
  • ROE (TTM)7.65%
  • Revenue (TTM)285.38M
  • Gross Margin (TTM)-
  • Net Margin (TTM)16.96%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Atea Pharmaceuticals Inc

There is no recent news for this security.

Profile

MORE
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The Company is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The Company is developing bemnifosbuvir (AT-527), which is an...
Jean-Pierre Sommadossi Ph.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Andrea Corcoran J.D.
Chief Financial Officer, Executive Vice President - Legal , Secretary
Nancy Agrawal Ph.D.
Executive Vice President, Preclinical Development
Address
225 Franklin Street, Suite 2100
Boston, MA
02110
United States

Top Peers

SYMBOLLASTCHG%CHG
CHRS
Coherus BioSciences Inc
7.91+0.46+6.17%
MOR
MorphoSys AG
5.06UNCHUNCH
AGEN
Agenus Inc
1.54+0.01+0.65%
MDXG
MiMedx Group Inc
3.61-0.03-0.82%
ALEC
Alector Inc
8.98+0.21+2.39%